Previous 10 | Next 10 |
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Laboratoires Théa, the leading independent eye care group in Europe, has selected IQVIA Technologie...
Insider buying decreased last week. Notable Insider Buys: IQVIA Holdings Inc., Odonate Therapeutics, Inc., Steel Partners Holdings L.P., OPKO Health, Inc., Fidelity National Financial, Inc. Notable Insider Sells: Walmart Inc., Elastic N.V., Facebook, Inc., Enphase Energy, Inc., Ma...
Q 2 Solutions, a leading global clinical trial laboratory services organization, resulting from an IQVIA and Quest Diagnostics joint venture, today announced a partnership with Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine. Q 2 Solutions will offer its...
Another year of double-digit decline in prescription opioid use in 2020 is expected to reduce usage in the United States to levels not seen since the early 2000s, completing a 20-year cycle that peaked in 2011 and has declined steadily since Decreases in prescription opioid ...
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a collaboration with Servier, an independent global pharmaceutical company, to reinvent their R&D clinical de...
The consolidation of biopharma customers is 'a risk to CROs’ as it can lead to downsizing of R&D budgets and outsourcing, Bank of America says in a note evaluating the impact on IQVIA Holdings (IQV) from the proposed merger between Alexion (ALXN) and AstraZeneca (AZN).Identifying I...
IQVIA™ (NYSE: IQV) said today that it is pleased to be a supporter of the Real World Evidence Leadership Forum, a group consisting of senior RWE executives from 18 major pharmaceutical companies. The forum acts as a non-competitive collaboration to understand, discuss and res...
Glenview Capital Management’s 13F portfolio value decreased from $3.63B to $3.19B this quarter. The number of positions increased from 43 to 45. They increased Myriad Genetics, while decreasing Quest Diagnostics, DaVita, and United Rentals during the quarter. The top three ...
ARKG aims to capitalize on a $9Tn TAM with the convergence of AI, DNA Sequencing and Gene-Editing. ARKG is up 149% YTD vs. the SPX return of 13%. Led by Cathie Wood, I think ARKG will be the best performing ARK Fund over the next 10 years. For further details see: ARKG: ...
Dan Loeb's 13F portfolio value increased from ~$7.30B to ~$10B this quarter. The number of positions increased from 36 to 47. Third Point added PG&E while dropping Baxter International and Raytheon Technologies during the quarter. The top three positions are at ~22% of the por...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...